Drug Trial Radar · NCT02486055
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Dec 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Nov 2015
Primary completion
Jan 2016
Study completion Jan 2016
Sponsor
- Lead sponsor
- BPGbioIndustry
- Sponsor type
- Industry
- First posted
- Jul 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, Phase I study of the bioavailability and safety of BPM31510 in healthy subjects dosed 2 or 3 times daily for 4 days, after an initial cohort of 6 subjects receiving a single dose (pre-study cohort). The pre-study cohort subjects will receive 1600 mg as a single administration. Cohort 1 and Cohort 2 will consist of 10 patients each. The cohorts may be enrolled sequentially.
Conditions
- Healthy
Interventions
BPM31510 Oral Nanosuspension 4%Drug
Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Days 1, 2, 8, and 15; baseline pre-dosing concentrations
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinilabs, Inc.
Eatontown, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.